A paradigm shift to prevent HIV drug resistance.
Bangsberg
David R
DR
Epidemiology and Prevention Interventions Center, Division of Infectious Diseases and Positive Health Program, San Francisco General Hospital, University of California San Francisco, California, United States of America. db@epi-center.ucsf.edu
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology; D024882:Drug Resistance, Viral; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D010349:Patient Compliance; D012367:RNA, Viral / Q000032:analysis; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D012367:RNA, Viral